Tumors harboring gene fusions previously described in naïve NSCLC tumors, even concerning unusual partners and breakpoints, seem to respond or control disease under treatments targeting the gene, such as for ALK, RET fusions, usually with maintaining EGFR-TKI [132]. This evidence concerns the gene ALK and non-small cell lung carcinoma.